Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 8, August, p. 1001–1009

doi: 10.17219/acem/121521

Publication type: review article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis

Huifeng Li1,C, Xiawei Fei1,A,C, Yanting Shen2,A, Zhenqi Wu1,F

1 Department of Urology, Qingpu Branch of Zhongshan Hospital affiliated to Fudan University, Shanghai, China

2 School of Biological Science and Medical Engineering, Southeast University, Nanjing, China


Previous studies have suggested that prostate-specific antigen (PSA) plays a role in the etiology of prostate cancer (PCa), and that polymorphisms of KLK3 may be associated with PCa. However, these results were conflicting. Therefore, we performed a meta-analysis to illuminate this problem. We searched the PubMed and Web of Science databases. Ten single nucleotide polymorphisms (SNPs) were involved in this meta-analysis. The pooled results showed that the minor alleles of rs1058205, rs2735839, rs174776, rs17632542, rs266849, rs266878, and rs2569735 were significantly associated with PCa. Compared to genotypes of the common homozygotes, the heterozygous genotypes of rs1058205, rs2735839, rs174776, rs17632542, rs266849, and rs266878 were significantly associated with PCa, as well as the homozygous genotypes of rs1058205, rs2735839, rs17632542, rs266878, rs266876, and rs2569735. Only rs2735839 was involved in the Gleason score (GS). The pooled results showed that when compared with GS ≥ 8 PCa, the A-allele was the protective factor for GS < 7 PCa. It was also a protective factor for GS ≥ 4+3 when compared to GS ≤ 3+4 PCa. A strong association was observed between PCa and rs1058205, rs2735839, rs266882, rs174776, rs17632542, rs266849, rs266878, rs266876, rs1058274, and rs2569735. The G-allele of rs2735839 was a risk factor for GS < 7 PCa when compared with the GS ≥ 8 PCa, as well as for the GS ≥ 4+3 when compared to the GS ≤ 3+4 PCa. Therefore, these SNPs may be valuable as biomarkers for PCa in the future.

Key words

KLK3, prostate-specific antigen, polymorphisms, prostate cancer, meta-analysis

References (35)

  1. Askari F, Parizi MK, Jessri M, Rashidkhani B. Fruit and vegetable intake in relation to prostate cancer in Iranian men: A case-control study. Asian Pac J Cancer Prev. 2014;15(13):5223–5227.
  2. Altekruse SF, Huang L, Cucinelli JE, McNeel TS, Wells KM, Oliver MN. Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States. Cancer ­Epidemiol Biomarkers Prev. 2010;19(6):1460–1467.
  3. Pilia G, Chen WM, Scuteri A, et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet. 2006;2(8):e132.
  4. Bansal A, Murray DK, Wu JT, Stephenson RA, Middleton RG, Meikle AW. Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. J Clin Endocrinol Metab. 2000;85(3):1272–1276.
  5. Ahn J, Berndt SI, Wacholder S, et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008;40(9):1032–1034.
  6. Wiklund F, Zheng SL, Sun J, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate. 2009;69(4):419–427.
  7. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316–321.
  8. Choe EK, Lee Y, Cho JY, et al. Search for genetic factor association with cancer-free prostate-specific antigen level elevation on the basis of a genome-wide association study in the Korean population. Eur J Cancer Prev. 2017;27(5):453–460. doi:10.1097/CEJ.0000000000000359
  9. Chen C, Xin Z. Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China. Medicine (Baltimore). 2017;96(10):e6280.
  10. Stegeman S, Amankwah E, Klein K, et al. A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer. Cancer Discov. 2015;5(4):368–379.
  11. He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify Gleason score 7 patients. Clin Cancer Res. 2014;20(19):5133–5139.
  12. Hu J, Qiu Z, Zhang L, Cui F. Kallikrein 3 and vitamin D receptor polymorphisms: Potentials environmental risk factors for prostate cancer. Diagn Pathol. 2014; 9:84.
  13. Shui IM, Lindström S, Kibel AS, et al. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014(6);65:1069–1075.
  14. Wang NN, Xu Y, Yang K, et al. Susceptibility loci associations with prostate cancer risk in Northern Chinese men. Asian Pac J Cancer Prev. 2013;14(5):3075–3078.
  15. Soni A, Bansal A, Mishra AK, et al. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a North Indian population. Genet Test Mol Biomarkers. 2012;16(8):835–840.
  16. Kwon EM, Holt SK, Fu R, et al. Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol. 2012;36(4):347–353.
  17. Kote-Jarai Z, Amin Al Olama A, et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet. 2011;129(6):687–694.
  18. Penney KL, Schumacher FR, Kraft P, et al. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011;32(6):853–859.
  19. Lindstrom S, Schumacher F, Siddiq A, et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS One. 2011;6(2):e17142.
  20. Ciampa J, Yeager M, Amundadottir L, et al. Large-scale exploration of gene–gene interactions in prostate cancer using a multistage genome-wide association study. Cancer Res. 2011;71(9):3287–3295.
  21. Parikh H, Wang Z, Pettigrew KA, et al. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet. 2011;129(6):675–685.
  22. Gudmundsson J, Besenbacher S, Sulem P, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med. 2010;2(62):62ra92.
  23. Gallagher DJ, Vijai J, Cronin AM, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res. 2010;16(10):2819–2832.
  24. Kader AK, Sun J, Isaacs SD, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009;69(11):1195–1205.
  25. Xu J, Isaacs SD, Sun J, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res. 2008;14(18):5819–5824.
  26. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316–321.
  27. Lai J, Kedda MA, Hinze K, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis. 2007;28(5):1032–1039.
  28. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2173–2177.
  29. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995;1(10):1089–1094.
  30. Lin JT, Wang JS, Jiann BP, et al. Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer. J Formos Med Assoc. 2005;104(11):864–867.
  31. Epstein JI, Allsbrook WC Jr. Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228–1242.
  32. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974.
  33. Orozco R, O’Dowd G, Kunnel B, Miller MC, Veltri RW. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 1998;51(2):186–195.
  34. Sakr WA, Tefilli MV, Grignon DJ, et al. Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology. 2000;56(5):730–734.
  35. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000;56(5):823–827.